Breast and ovarian cancer vaccines
The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
1. A composition comprising an isolated and purified plasmid comprising a nucleotide sequence encoding the fusion protein of SEQ ID NO: 79, the fusion protein comprising a plurality of epitopes, wherein the epitopes comprise the HER2 amino acid sequence of SEQ ID NO: 60, the IGFBP-2 amino acid sequence of SEQ ID NO: 54, and the IGF1R amino acid sequence of SEQ ID NO: 73.
2. The composition of claim 1 , wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: 57.
3. The composition of claim 1 , wherein the nucleotide sequence comprises the nucleic acid sequence of SEQ ID NO: 43.
4. The composition of claim 1 , wherein the nucleotide sequence comprises the nucleic acid sequence of SEQ ID NO: 63.
5. The composition of claim 1 , wherein the plurality of epitopes comprises one or more linkers between one or more epitopes.
6. The composition of claim 1 , wherein the nucleotide sequence comprises a nucleic acid sequence of SEQ ID NO: 76.
7. The composition of claim 1 , wherein the composition further comprises an excipient.
8. A composition comprising an isolated and purified plasmid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 79.
9. A method of inducing an immune response in a subject having breast or ovarian cancer, the method comprising: a) administering the composition of claim 1 to the subject; and b) eliciting an immune response to a breast or ovarian cancer cell in the subject.
10. A method of inducing an immune response in a subject having breast or ovarian cancer, the method comprising: a) administering the composition of claim 1 to the subject; and b) eliminating a number of breast or ovarian cancer cells in the subject.
11. The method of claim 9 , wherein the immune response is a Type I immune response.
12. The method of claim 9 , wherein the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1.
13. The method of claim 9 , wherein the immune response is characterized by a ratio of IFNg production to IL-10 production that is greater than 1.